Washington Roundup

• The FDA's Office of Prescription Drug Promotion, Division of Professional Drug Promotion issued a letter to ONY Inc., of Amherst, N.Y., stating that materials on its website are false or misleading because they present unsubstantiated superiority claims for Infasurf, omit important risk information and make unsubstantiated claims for the product.